Clinical Trials for Pancreas Cancer

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with well/moderately differentiated, metastatic, unresectable, somatostatin receptor–positive pancreatic NETs (ECOG 0–2) who are PRRT- and sunitinib-naïve, allowing prior SSA and up to one prior systemic therapy. Investigates combination of lutetium Lu 177 dotatate PRRT and sunitinib (multi–TKI targeting VEGFR/PDGFR) to define safety/MTD and assess preliminary efficacy.

ClinicalTrials.gov ID: NCT05687123

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-proven locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2, minimal prior therapy allowed) receive standard multiagent chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation of the primary tumor and pembrolizumab, an anti–PD-1 antibody. Aims to test whether local ablation can enhance immune priming and systemic activity of PD-1 blockade alongside chemotherapy.

ClinicalTrials.gov ID: NCT06831136

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.

ClinicalTrials.gov ID: NCT07145255

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic ductal adenocarcinoma harboring a KRASG12D mutation after prior cytotoxic therapy receive IV mesenchymal stromal cell–derived exosomes loaded with KRASG12D siRNA (iExosomes) on days 1, 4, and 10 of 14‑day cycles, up to 3 cycles with possible extension. The investigational therapy delivers siRNA via exosomes to degrade KRASG12D mRNA and suppress downstream MAPK signaling; eligibility requires ECOG 0–1 and adequate organ function, with treated/stable brain metastases permitted.

ClinicalTrials.gov ID: NCT03608631

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with pancreatic ductal adenocarcinoma limited to the peritoneum (PCI ≤8, ECOG 0–1), including resectable/borderline/locally advanced disease and select patients with up to 4 months of prior FOLFIRINOX/NALIRIFOX without progression, receive intraperitoneal paclitaxel (microtubule stabilizer) on days 1 and 8 plus systemic NALIRIFOX (5-FU/leucovorin, liposomal irinotecan [topoisomerase I inhibitor], oxaliplatin) on day 1 of 14-day cycles up to 12 cycles. The trial evaluates safety and signals of efficacy, with goals of peritoneal disease control and potential conversion to surgery.

ClinicalTrials.gov ID: NCT07030283

A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with newly diagnosed, measurable metastatic pancreatic ductal adenocarcinoma and good performance status (ECOG 0–1) who have not received prior chemotherapy for metastatic disease (prior adjuvant/perioperative gemcitabine allowed if completed ≥6 months before metastasis). Treatment is single-arm pegcetacoplan (a proximal complement C3 inhibitor) added to first-line mFOLFIRINOX given q14 days for up to 8 cycles, evaluating safety plus preliminary antitumor and thromboembolism-reduction signals.

ClinicalTrials.gov ID: NCT07214298

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with locally advanced or metastatic pancreatic, lung, breast, and colorectal cancers who have progressed after standard treatments and exhibit tumor uptake of [68Ga]Ga-NNS309. It evaluates the safety and preliminary activity of the investigational radioligand [177Lu]Lu-NNS309, which targets specific tumor markers, though its exact mechanism of action is undisclosed.

ClinicalTrials.gov ID: NCT06562192

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors, especially those with DNA damage repair deficiencies or PTGR1 overexpression, who have progressed after standard therapies. Patients receive LP-184, a PTGR1-activated prodrug that induces DNA double-strand breaks, as monotherapy or in combination with spironolactone (for recurrent glioblastoma) or olaparib (for triple negative breast cancer).

ClinicalTrials.gov ID: NCT05933265

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic solid tumors (including NSCLC, pancreatic, colorectal, or other types) harboring KRAS mutations (G12A, G12C, G12D, G12S, G12V) or amplification are eligible for treatment with BBO-11818, a selective oral pan-KRAS inhibitor, as monotherapy or in combination with pembrolizumab, platinum-based chemotherapy plus pemetrexed, or cetuximab.

ClinicalTrials.gov ID: NCT06917079